Alercell, Inc. aims to streamline the process for testing of cancer and Leukemia in developing cancer testing technology through very early genetic detection. We imagine a world where testing detects disease before any clinical symptoms.
Alercell, believes that AI can provide new insights into the biological processes driving diseases, help identify new therapeutic targets, and guide the design molecules optimized to best inhibit those targets. In 2024 Alercell is introducing AI inside its operations. For Alercell the next frontier is Theragnostic, intervening on genes mutations or methylation prior to illness setting in.
Lena Q51 the most advanced Leukemia genetic diagnostic test